Gene therapy for Parkinson's motor complications
Part of Brain & nervous system clinical trials.
This trial tests a gene therapy (AAV2-hAADC) delivered directly into the brain to help people with advanced Parkinson's disease whose medication doesn't work as well as it used to. The goal is to improve the brain's ability to make dopamine and reduce daily 'off' time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had Parkinson's disease for more than 3 years, and your symptoms must have started before you turned 50.
- You must experience at least 3 hours of 'off' time (when medication effects wear off) each day.
- You must have a stable Parkinson's medication plan for at least 4 weeks before the screening.
- You must be able to stop taking blood thinners for at least 2 weeks before and after the surgery.
- You cannot have had any prior brain surgery, including deep brain stimulation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new gene therapy delivered directly into a specific brain region (the subthalamic nucleus) using stereotactic surgery. It's designed for people with advanced Parkinson's disease who no longer respond well to standard medications or have severe side effects.
This study tests a new gene therapy called LY-N001, which is injected directly into the brain. It is for people with moderate to advanced Parkinson's disease who have a specific genetic change in the GBA1 gene. The goal is to see if this treatment is safe and can help improve symptoms.
This trial tests a new gene therapy called ZR001 for people with Parkinson's disease. It involves a one-time surgery to inject the therapy into the brain, and researchers want to see if it's safe and can help improve movement symptoms.
This trial tests a gene therapy for people with advanced Parkinson's disease (at least 10 years since diagnosis). It uses a special infusion to deliver treatment directly into the brain. The goal is to see if it can improve motor symptoms.
This trial tests a gene therapy (AAV2-GDNF) to see if it can slow or improve symptoms of Parkinson's disease. It is for people who have had moderate Parkinson's for 4 to 10 years and still respond to levodopa therapy.
This trial tests a new gene therapy called BBM-P002 for Parkinson's disease. It aims to see if the treatment is safe and tolerable, and may help people with moderate to advanced Parkinson's who have had the condition for at least 5 years.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.